Shanghai Chaoyang Pharmaceutical

Shanghai Chaoyang Pharmaceutical is a clinical-stage biotechnology company specializing in targeted protein degradation (TPD) therapies for oncology and autoimmune diseases. Founded in 2021 and operating as a subsidiary of Yuandong Bio, the company leverages its proprietary Protein Homeostasis Technology and Degrader Antibody Conjugate (DAC) platforms to discover and develop molecular glues, PROTACs, and DACs. Its lead candidate, HP-001, is a novel oral CRBN-based molecular glue degrader targeting IKZF1/3, currently in Phase 1/2 clinical trials for hematologic malignancies such as multiple myeloma and non-Hodgkin lymphoma. Additionally, its brain-penetrant BTK PROTAC degrader, HP-002, has entered clinical development for B-cell malignancies. Through its advanced computer-aided drug design (CADD) capabilities, Shanghai Chaoyang Pharmaceutical continues to expand its pipeline of next-generation therapeutics to address undruggable targets.